Casanueva, F. F. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006).
Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011).
Wan, X. Y. et al. Overview of the 2022 WHO classification of pituitary adenomas/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives. Curr. Med. Sci. 42, 1111–1118 (2022).
Stiles, C. E., Tetteh-Wayoe, E. T., Bestwick, J., Steeds, R. P. & Drake, W. M. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline. J. Clin. Endocrinol. Metab. 104, 523–538 (2018).
Hage, C. & Salvatori, R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J. Clin. Endocrinol. Metab. 105, dgaa652 (2020).
Giese, S., Nasi-Kordhishti, I. & Honegger, J. Outcomes of transsphenoidal microsurgery for prolactinomas – a contemporary series of 162 cases. Exp. Clin. Endocrinol. Diabetes 129, 163–171 (2021).
Yagnik, K. J. et al. Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24, 978–988 (2021).
Zamanipoor Najafabadi, A. H. et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32–e41 (2020).
Glezer, A. & Bronstein, M. D. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary 23, 65–69 (2020).
Luger, A. et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur. J. Endocrinol. 185, G1–G33 (2021).
Molitch, M. E. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur. J. Endocrinol. 172, R205–R213 (2015).
di Filippo, L., Doga, M., Resmini, E. & Giustina, A. Hyperprolactinemia and bone. Pituitary 23, 314–321 (2020).
Burman, P. et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur. J. Endocrinol. 187, 593–605 (2022).
Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924–926 (2008).
Swiglo, B. A. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93, 666–673 (2008).
Fleseriu, M. et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 9, 847–875 (2021).
Chanson, P. & Maiter, D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019).
Shimon, I. Giant prolactinomas. Neuroendocrinology 109, 51–56 (2019).
Herman, V., Fagin, J., Gonsky, R., Kovacs, K. & Melmed, S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71, 1427–1433 (1990).
Melmed, S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937–950 (2020).
Li, C. et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat. Commun. 11, 2506 (2020).
Brandi, M. L. et al. Multiple endocrine neoplasia type 1: latest insights. Endocr. Rev. 42, 133–170 (2021).
Salenave, S. et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J. Clin. Endocrinol. Metab. 100, 1177–1186 (2015).
Le Bras, M. et al. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. Eur. J. Endocrinol. 185, 863–873 (2021).
Sonigo, C. et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J. Clin. Invest. 122, 3791–3795 (2012).
Barber, T. M. et al. Mechanisms of central hypogonadism. Int. J. Mol. Sci. 22, 8217 (2021).
Sehemby, M. et al. Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline. J. Clin. Endocrinol. Metab. 105, e4551–e4557 (2020).
Rudman, Y., Duskin-Bitan, H., Masri-Iraqi, H., Akirov, A. & Shimon, I. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25, 882–890 (2022).
Molitch, M. E. Diagnosis and treatment of pituitary adenomas: a review. J. Am. Med. Assoc. 317, 516–524 (2017).
Peric, B. et al. Obesity and hypercholesterolemia in patients with prolactinomas: could DHEA-S and growth hormone be the missing link? Endocr. Res. 41, 200–206 (2016).
Pinzone, J. J. et al. Primary medical therapy of micro- and macroprolactinomas in men. J. Clin. Endocrinol. Metab. 85, 3053–3057 (2000).
Iglesias, P. et al. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm. Metab. Res. 50, 791–796 (2018).
Colao, A. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704–1711 (2004).
Tirosh, A., Benbassat, C., Lifshitz, A. & Shimon, I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18, 108–115 (2015).
Fleseriu, M. et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3888–3921 (2016).
Samperi, I., Lithgow, K. & Karavitaki, N. Hyperprolactinaemia. J. Clin. Med. 8, E2203 (2019).
Kaiser, U. & Ho, K. Pituitary physiology and diagnostic evaluation. In Williams Textbook of Endocrinology (eds Melmed, S., Koenig, R., Rosen, C. J., Auchus, R. J. & Goldfine, A, B.) 184–235 (Elsevier, 2019).
Karavitaki, N. et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. 65, 524–529 (2006).
Alexopoulou, O. et al. Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas. Endocrine 73, 166–176 (2021).
De Sousa, S. M. C. et al. Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. Pituitary 20, 676–682 (2017).
Burke, W. T. et al. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J. Neurosurg. 133, 321–328 (2019).
Cote, D. J. et al. Oral contraceptive and menopausal hormone therapy use and risk of pituitary adenoma: cohort and case-control analyses. J. Clin. Endocrinol. Metab. 107, e1402–e1412 (2022).
Schievink, W. I. et al. Hyperprolactinemia due to spontaneous intracranial hypotension. J. Neurosurg. 122, 1020–1025 (2015).
Tsur, A., Dreyfuss, E., Ness-Abramof, R., Pollack, R. & Cahn, A. Role of cannulated prolactin test in evaluation of hyperprolactinemia – a retrospective study. Endocr. Pract. 26, 1304–1311 (2020).
Whyte, M. B. et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18, 319–325 (2015).
Mennella, J. A. & Pepino, M. Y. Short-term effects of alcohol consumption on the hormonal milieu and mood states in nulliparous women. Alcohol 38, 29–36 (2006).
Petersenn, S. Biochemical diagnosis in prolactinomas: some caveats. Pituitary 23, 9–15 (2020).
Delcour, C., Robin, G., Young, J. & Dewailly, D. PCOS and hyperprolactinemia: what do we know in 2019? Clin. Med. Insights Reprod. Health 13, 1179558119871921 (2019).
Honegger, J. et al. Diagnosis of primary hypophysitis in Germany. J. Clin. Endocrinol. Metab. 100, 3841–3849 (2015).
Borba, V. V., Zandman-Goddard, G. & Shoenfeld, Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101324 (2019).
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V. & Melmed, S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10, 804–826 (2022).
de Vries, F. et al. Opioids and their endocrine effects: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, 1020–1029 (2020).
Molitch, M. E. Drugs and prolactin. Pituitary 11, 209–218 (2008).
Zhu, Y. et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr. Res. 237, 20–25 (2021).
Aliberti, L. et al. Hypeprolactinemia: still an insidious diagnosis. Endocrine 72, 928–931 (2021).
Overgaard, M. & Pedersen, S. M. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin. Chem. Lab. Med. 55, 1744–1753 (2017).
Saleem, M., Martin, H. & Coates, P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin. Biochem. Rev. 39, 3–16 (2018).
Wallace, I. R. et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95, 3268–3271 (2010).
Olukoga, A. O. & Kane, J. W. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. 51, 119–126 (1999).
Raverot, V. et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary 25, 653–657 (2022).
Nachtigall, L. B. et al. Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey. Pituitary 22, 37–45 (2019).
Gallo-Bernal, S. et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease after the use of gadolinium-based contrast agents: a review for the cardiovascular imager. Diagnostics 12, 1816 (2022).
Alkabbani, A. G. et al. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary 17, 97–102 (2014).
Varlamov, E. V., Hinojosa-Amaya, J. M. & Fleseriu, M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary 23, 16–26 (2020).
Lombardi, M. et al. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Horm. Metab. Res. 46, 939–942 (2014).
Schlechte, J., Dolan, K., Sherman, B., Chapler, F. & Luciano, A. The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412–418 (1989).
Hinojosa-Amaya, J. M., Varlamov, E. V., McCartney, S. & Fleseriu, M. Pituitary magnetic resonance imaging use in the posttreatment follow-up of secreting pituitary adenomas. In Pituitary Tumors: A Comprehensive and Interdisciplinary Approach (eds J. Honegger, J., Reincke, M. & Petersenn, S.) 447–455 (Academic Press, 2021).
Kreutz, J. et al. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57, 679–684 (2015).
Burlacu, M. C., Maiter, D., Duprez, T. & Delgrange, E. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63, 323–331 (2019).
Dogansen, S. C. et al. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21, 347–354 (2018).
Biagetti, B. et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur. J. Endocrinol. 185, 587–595 (2021).
Eroukhmanoff, J. et al. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur. J. Endocrinol. 176, 323–328 (2017).
Akinduro, O. O. et al. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. 129, e686–e694 (2019).
Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428–2436 (2009).
Xia, M. Y., Lou, X. H., Lin, S. J. & Wu, Z. B. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59, 50–61 (2018).
Melmed, S. et al. Clinical biology of the pituitary adenoma. Endocr. Rev. 43, 1003–1037 (2022).
Kuhn, E., Weinreich, A. A., Biermasz, N. R., Jorgensen, J. O. L. & Chanson, P. Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. Eur. J. Endocrinol. 185, 99–108 (2021).
Honegger, J., Nasi-Kordhishti, I., Aboutaha, N. & Giese, S. Surgery for prolactinomas – a better choice? Pituitary 23, 45–51 (2019).
Bashari, W. A. et al. Modern imaging of pituitary adenomas. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101278 (2019).
Bashari, W. A. et al. 11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. Pituitary 25, 573–586 (2022).
Bakker, L. E. H. et al. Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary 25, 587–601 (2022).
Prior, J. C., Cox, T. A., Fairholm, D., Kostashuk, E. & Nugent, R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J. Clin. Endocrinol. Metab. 64, 391–394 (1987).
Akirov, A. & Rudman, Y. The role of aromatase inhibitors in male prolactinoma. J. Clin. Med. 12, 1437 (2023).
Burnett-Bowie, S. A., McKay, E. A., Lee, H. & Leder, B. Z. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 94, 4785–4792 (2009).
Ribeiro, R. S. & Abucham, J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur. J. Endocrinol. 161, 163–169 (2009).
Salenave, S., Trabado, S., Maione, L., Brailly-Tabard, S. & Young, J. Male acquired hypogonadotropic hypogonadism: diagnosis and treatment. Ann. Endocrinol. 73, 141–146 (2012).
Drincic, A. et al. Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile. Pituitary 6, 5–10 (2003).
Mancini, T., Casanueva, F. F. & Giustina, A. Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008).
Mazziotti, G. et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14, 299–306 (2011).
Giraldi, E. A. & Ioachimescu, A. G. The role of dopamine agonists in pituitary adenomas. Endocrinol. Metab. Clin. North Am. 49, 453–474 (2020).
Moraes, A. B., Silva, C. M., Vieira Neto, L. & Gadelha, M. R. Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. 79, 447–456 (2013).
Maiter, D. & Delgrange, E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014).
Huang, H. Y., Lin, S. J., Zhao, W. G. & Wu, Z. B. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: a quantitative and systematic review. Metab. Brain Dis. 33, 969–976 (2018).
Lee, Y. et al. Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol. Metab. 29, 280–292 (2014).
Tirosh, A., Benbassat, C. & Shimon, I. Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas. Endocr. Pract. 21, 1240–1247 (2015).
Johnson, M. D., Woodburn, C. J. & Vance, M. L. Quality of life in patients with a pituitary adenoma. Pituitary 6, 81–87 (2003).
Duskin-Bitan, H. & Shimon, I. Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020).
Stumpf, M. A. M. et al. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary 26, 187–196 (2023).
De Sousa, S. M. C. et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J. Clin. Endocrinol. Metab. 105, e108–e118 (2020).
Ioachimescu, A. G., Fleseriu, M., Hoffman, A. R., Vaughan Iii, T. B. & Katznelson, L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur. J. Endocrinol. 180, 31–40 (2019).
Hinojosa-Amaya, J. M. et al. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front. Endocrinol. 11, 579606 (2020).
Buchfelder, M., Zhao, Y. & Schlaffer, S. M. Surgery for prolactinomas to date. Neuroendocrinology 109, 77–81 (2019).
Lam, G., Mehta, V. & Zada, G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg. Focus. 32, E2 (2012).
Steeds, R. et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin. Endocrinol. 90, 662–669 (2019).
Souteiro, P., Belo, S. & Carvalho, D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary 23, 38–44 (2020).
Paepegaey, A. C. et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J. Endocr. Soc. 1, 221–230 (2017).
Vilar, L. et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front. Endocrinol. 6, 11 (2015).
Kwancharoen, R. et al. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17, 451–456 (2014).
Greenman, Y. Prolactinomas and menopause: any changes in management? Pituitary 23, 58–64 (2020).
Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006).
Primeau, V., Raftopoulos, C. & Maiter, D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. 166, 779–786 (2012).
Kreutzer, J. et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur. J. Endocrinol. 158, 11–18 (2008).
Tampourlou, M., Trifanescu, R., Paluzzi, A., Ahmed, S. K. & Karavitaki, N. Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur. J. Endocrinol. 175, R89–R96 (2016).
Baussart, B. et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur. J. Endocrinol. 185, 783–791 (2021).
Micko, A., Vila, G., Hoftberger, R., Knosp, E. & Wolfsberger, S. Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery 85, 508–515 (2019).
Ma, Q. et al. The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front. Endocrinol. 9, 636 (2018).
Wright, K. et al. Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg. 154, e349–e369 (2021).
Losa, M., Mortini, P., Barzaghi, R., Gioia, L. & Giovanelli, M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J. Clin. Endocrinol. Metab. 87, 3180–3186 (2002).
Osorio, R. C. et al. Correlation between tumor volume and serum prolactin and its effect on surgical outcomes in a cohort of 219 prolactinoma patients. J. Neurosurg. 138, 1669–1679 (2022).
Ikeda, H., Watanabe, K., Tominaga, T. & Yoshimoto, T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin. Neurol. Neurosurg. 115, 1621–1625 (2013).
Zielinski, G., Ozdarski, M., Maksymowicz, M., Szamotulska, K. & Witek, P. Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front. Endocrinol. 11, 439 (2020).
Abou-Al-Shaar, H. et al. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus. Pituitary 25, 508–519 (2022).
Force, B. K. et al. Endoscopic endonasal transsphenoidal surgery for patients with prolactinomas: indications and outcomes. World Neurosurg. 168, e626–e635 (2022).
Donoho, D. A. & Laws, E. R. Jr. The role of surgery in the management of prolactinomas. Neurosurg. Clin. North Am. 30, 509–514 (2019).
Vroonen, L. et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167, 651–662 (2012).
Menucci, M., Quinones-Hinojosa, A., Burger, P. & Salvatori, R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14, 68–74 (2011).
Nakhleh, A. et al. Management of cystic prolactinomas: a review. Pituitary 21, 425–430 (2018).
Yousem, D. M., Arrington, J. A., Zinreich, S. J., Kumar, A. J. & Bryan, R. N. Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology 170, 239–243 (1989).
Hage, C. & Salvatori, R. Speed of response to dopaminergic agents in prolactinomas. Endocrine 75, 883–888 (2022).
Faje, A. et al. Dopamine agonists can reduce cystic prolactinomas. J. Clin. Endocrinol. Metab. 101, 3709–3715 (2016).
Colao, A. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325–331 (2003).
Mazziotti, G. et al. Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011).
Shimon, I., Benbassat, C., Tzvetov, G. & Grozinsky-Glasberg, S. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary 14, 11–15 (2011).
Shimon, I. et al. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine 65, 656–661 (2019).
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. & Tourniaire, J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2102–2107 (1997).
Fainstein Day, P. et al. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and Ki-67 expression in tumor tissue. Front. Horm. Res. 38, 50–58 (2010).
Nishioka, H., Haraoka, J. & Akada, K. Growth potential of prolactinomas in men: is it really different from women?. Surg. Neurol. 59, 386–390 (2003).
Schaller, B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol. Lett. 26, 152–159 (2005).
Melmed, S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest. 112, 1603–1618 (2003).
Lasolle, H., Ilie, M. D. & Raverot, G. Aggressive prolactinomas: how to manage? Pituitary 23, 70–77 (2020).
Raverot, G. et al. Aggressive pituitary tumours and pituitary carcinomas. Nat. Rev. Endocrinol. 17, 671–684 (2021).
Maiter, D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109, 42–50 (2019).
Raverot, G. et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–G24 (2018).
McCormack, A. et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur. J. Endocrinol. 178, 265–276 (2018).
Losa, M. et al. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J. Neurooncol. 126, 519–525 (2016).
Lasolle, H. et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur. J. Endocrinol. 176, 769–777 (2017).
Elbelt, U. et al. Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas – a German survey. J. Clin. Endocrinol. Metab. 105, e660–e675 (2020).
Goichot, B. et al. Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. Clin. Endocrinol. 98, 633–637 (2023).
Ilie, M. D. et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur. J. Endocrinol. 187, 685–696 (2022).
Raverot, G. & Ilie, M. D. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101712 (2022).
Zhang, D. et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 104, 1929–1936 (2019).
Cooper, O. et al. EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J. Clin. Endocrinol. Metab. 106, e917–e925 (2021).
Bazuhair, T., Aleid, B. & Almalki, M. Effect of tamoxifen on the management of dopamine agonist-resistant prolactinomas: a systematic review. Cureus 15, e35171 (2023).
Petersenn, S. & Heaney, A. P. Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. Rev. Endocr. Metab. Disord. 21, 277–286 (2020).
Casanueva, F. F. et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a Pituitary Society statement. Pituitary 20, 489–498 (2017).
Zhong, H. P. et al. Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy. Endocrine 66, 477–484 (2019).
Sant’ Anna, B. G. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 23, 120–128 (2020).
Martinez de LaPiscina, I. et al. Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas. Eur. J. Endocrinol. 185, 485–496 (2021).
Tatsi, C. & Stratakis, C. A. Aggressive pituitary tumors in the young and elderly. Rev. Endocr. Metab. Disord. 21, 213–223 (2020).
Breil, T. et al. Clinical features and response to treatment of prolactinomas in children and adolescents: a retrospective single-centre analysis and review of the literature. Horm. Res. Paediatr. 89, 157–165 (2018).
Brichta, C. M., Wurm, M., Krebs, A., Schwab, K. O. & van der Werf-Grohmann, N. Start low, go slowly – mental abnormalities in young prolactinoma patients under cabergoline therapy. J. Pediatr. Endocrinol. Metab. 32, 969–977 (2019).
Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A. & Muller, H. L. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur. J. Pediatr. 177, 125–132 (2018).
Culpin, E. et al. Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition? Pituitary 21, 474–479 (2018).
Jankowski, P. P. et al. Pituitary tumor apoplexy in adolescents. World Neurosurg. 83, 644–651 (2015).
McCormack, A. Childhood-onset prolactinomas – should earlier surgery be considered? Clin. Endocrinol. 95, 571–573 (2021).
Chanson, P. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101711 (2022).
Alosaimi, F. D. et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int. J. Psychiatry Clin. Pract. 22, 274–281 (2018).
Haddad, P. M. & Wieck, A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291–2314 (2004).
Chang, S. C., Chen, C. H. & Lu, M. L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen. Hosp. Psychiatry 30, 378–380 (2008).
Allard, L. et al. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. Eur. J. Endocrinol. 183, 221–231 (2020).
Besag, F. M. C., Vasey, M. J. & Salim, I. Is adjunct aripiprazole effective in treating hyperprolactinemia induced by psychotropic medication? A narrative review. CNS Drugs 35, 507–526 (2021).
Balint-Peric, L. A. & Prelevic, G. M. Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. Gynecol. Endocrinol. 11, 275–280 (1997).
Karunakaran, S., Page, R. C. & Wass, J. A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54, 295–300 (2001).
Santharam, S. et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin. Endocrinol. 89, 346–353 (2018).
Indirli, R. et al. Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm. Cancer 10, 120–127 (2019).
Maor, Y. & Berezin, M. Hyperprolactinemia in postmenopausal women. Fertil. Steril. 67, 693–696 (1997).
Shimon, I. et al. Women with prolactinomas presented at the postmenopausal period. Endocrine 47, 889–894 (2014).
Santharam, S. et al. Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin. Endocrinol. 87, 508–514 (2017).
Dekkers, O. M. et al. Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur. J. Endocrinol. 173, 269–273 (2015).
Soto-Pedre, E., Newey, P. J., Bevan, J. S. & Leese, G. P. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr. Connect. 6, 580–588 (2017).
Hembree, W. C. et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 102, 3869–3903 (2017).
Nota, N. M. et al. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia 49, e12666 (2017).
Defreyne, J. et al. Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment. LGBT Health 4, 328–336 (2017).
Raven, L. M., Guttman-Jones, M. & Muir, C. A. Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment. Endocrine 72, 524–528 (2021).
Cowden, E. A., Ratcliffe, W. A., Ratcliffe, J. G., Dobbie, J. W. & Kennedy, A. C. Hyperprolactinaemia in renal disease. Clin. Endocrinol. 9, 241–248 (1978).
Hou, S. H., Grossman, S. & Molitch, M. E. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245–249 (1985).
Rodriguez-Puyol, D. et al. Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients. J. Clin. Endocrinol. Metab. 62, 352–356 (1986).
Veldhuis, J. D., Iranmanesh, A., Wilkowski, M. J. & Samojlik, E. Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. Eur. J. Endocrinol. 131, 489–498 (1994).
Lo, J. C. et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial. Int. 21, 190–196 (2017).
Weizman, R. et al. Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemodialysis. Psychosom. Med. 45, 259–269 (1983).
Schaefer, R. M., Kokot, F., Kuerner, B., Zech, M. & Heidland, A. Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. Int. J. Artif. Organs 12, 445–449 (1989).